melanoma

dart board miss failure
Biotech

Cancer vaccine's 'narrow' fail won't stop IO heading to FDA

IO Biotech’s cancer vaccine has “narrowly” failed to beat Keytruda in a phase 3 melanoma trial, but the company remains hopeful of a path to approval.
James Waldron Aug 11, 2025 9:48am
arrow choose one big pick forward many

Scancell picks winner from phase 2 cancer vaccine face-off

Jul 22, 2025 9:38am
Image of a neon sign with the word no lit up next to an unlit yes

Replimune's request for melanoma approval rejected by FDA

Jul 22, 2025 8:45am
pendulum silver metallic spheres on coloured background with drop shadow

As investors pivot from cell therapy, Immatics keeps the faith

Jun 6, 2025 3:50am
pile of cash piggy bank money cash dollars bills spend

Pathos AI's $365M series D to fund trial of Novo tumor drug

May 15, 2025 10:20am
An open book with pages turning on a wooden table set

Erasca looks to partner off late-stage melanoma asset

May 13, 2025 10:38am